Will Peregrine Pharmaceuticals Earnings Reveal Any New Secrets Against Celgene?
The biopharma company is looking to revolutionize how we fight cancer, but enthusiasm from earlier this year has largely disappeared. Can Peregrine's bavituximab beat out Celgene's Abraxane? Find out here.
This Week in Biotech: Part 2
With 11 noteworthy biotech events this week, Part 2 of this weekly series looks at six clinical updates that amazed investors, including a mid-stage cancer trial that sent shares of one company up 74% while a large pharmaceutical company chalked up another failure.
Zoetis Stock: 3 Key Investing Lessons from 2013
Will new developments from Novartis, Merck, and Eli Lilly threaten Zoetis’ dominance of the animal health business? What 3 key lessons should investors learn from Zoetis’ performance throughout 2013 since it was spun off from Pfizer?